Successful treatment with weekly paclitaxel in a patient with recurrent endornetrial cancer. A case report

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Case Report

S-J Chang¹, T-C Chen², T-Y Wang³, C-Y Hsu⁴, H-S Chen², Y-C Yang^5,*

Show Less

¹ Fellow, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taiwan

² Attending, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taiwan

³ Lecturer, Mackay Junior college of Nursing, Attending, Department of Pathology, Mackay Memorial Hospital, Taiwan

⁴ Attending, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taiwan

⁵ Attending, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taiwan

Eur. J. Gynaecol. Oncol. 2003, 24(5), 377–378;

Published: 10 October 2003

Download PDF

Cite

Abstract

The best treatment for recurrent endometrial cancer is still uncertain, although weekly paclitaxel has shown some promise in the management of this disease. In this report we present a patient with recurrent endometrial cancer treated with weekly paclitaxel. Serial power Doppler angiography was used to assess the effects of therapy. The response was good, suggesting that recurrent endometrial cancer may be successfully treated with weekly paclitaxel and effectively monitored with power Doppler angiography.

Keywords

Recurrent endometrial cancer

Weekly paclitaxel

Previous article in this issue

Next article in this issue

Eur. J. Gynaecol. Oncol. Print ISSN 0392-2936 Electronic ISSN 2709-0086